Seattle Genetics, Inc. SGEN today highlighted ongoing clinical
development programs for ADCETRIS (brentuximab vedotin) in frontline
Hodgkin lymphoma (HL) and mature T-cell lymphoma (MTCL) and progress
with collaborator antibody-drug conjugate (ADC) programs that were
presented at the 49th Annual Meeting of the American Society
of Clinical Oncology being held May 31 – June 4, 2013, in Chicago, IL.
The phase 3 clinical trials, called ECHELON-1 and ECHELON-2, are
evaluating ADCETRIS for the frontline treatment of HL and MTCL,
including patients with systemic anaplastic large cell lymphoma (sALCL)
and other types of peripheral T-cell lymphoma. ADCETRIS is an ADC
directed to CD30, a defining marker of HL and sALCL, which was granted
accelerated approval by the FDA in August 2011 for relapsed HL
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in